Nguyen Julie M V, Zigras Tiffany, Gayowsky Anastasia, Marcucci Maura, Vicus Danielle, Nica Andra, Hogen Liat, Costa Andrew, Perez Richard
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, McMaster University, Hamilton, Ontario, Canada.
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ontario, Canada.
Gynecol Oncol. 2025 Jul;198:137-145. doi: 10.1016/j.ygyno.2025.05.021. Epub 2025 Jun 7.
The relationship between frailty and both short- and long-term outcomes remains underexplored in gynecologic oncology (GO). We sought to evaluate the association of frailty with 30-day complications, costs and mortality, and long-term survival following surgery.
A population-based observational retrospective cohort study of patients undergoing a laparotomy for a gynecologic malignancy between 2009 and 2021 was conducted using Ontario province-wide databases. Frailty was defined using the preoperative frailty index (pFI) and the John Hopkins Adjusted Clinical Groups frailty indicator (ACG).
Among 21,359 patients, 1405 (6.6 %) and 1144 (5.4 %) were frail using the pFI and ACG. Frailty as assessed by the pFI was associated with an increased risk of 30-daycomplications (25.7 % vs 7.4 %, p < 0.0001), 30-day mortality (2.9 % vs 0.5 %, p < 0.0001), 90-day mortality (7.1 % vs 1.4 %, p < 0.0001), 30-day mean healthcare costs ($16,478 vs $9306, p < 0.0001), and lower median 5 year-survival (3.28 years versus not reached). Frailty was independently associated with 30-day complications (OR 1.92, 95 % CI 1.63-2.27, p < 0.0001)) in multivariable regression analysis adjusting for age, income quintile, primary cancer, stage, type of surgery and neoadjuvant chemotherapy, and with lower 5-year survival (HR 1.27, 95 % CI 1.16-1.38, p < 0.0001) adjusting for age, primary cancer, stage, neoadjuvant chemotherapy and comorbidities. Results for these outcomes were similar using the ACG. The ROC analysis revealed similar area under the curve for both indices.
Frailty as measured by both the pFI and ACG was predictive of outcomes including increased postoperative morbidity and mortality, and 5-year survival. Strategies to optimize perioperative care for frailty are required.
在妇科肿瘤学(GO)领域,虚弱与短期和长期预后之间的关系仍未得到充分研究。我们旨在评估虚弱与30天并发症、费用和死亡率以及手术后长期生存之间的关联。
利用安大略省全省范围的数据库,对2009年至2021年间因妇科恶性肿瘤接受剖腹手术的患者进行了一项基于人群的观察性回顾性队列研究。使用术前虚弱指数(pFI)和约翰·霍普金斯调整临床分组虚弱指标(ACG)来定义虚弱。
在21359例患者中,使用pFI和ACG评估分别有1405例(6.6%)和1144例(5.4%)为虚弱。pFI评估的虚弱与30天并发症风险增加相关(25.7%对7.4%,p<0.0001)、30天死亡率增加相关(2.9%对0.5%,p<0.0001)、90天死亡率增加相关(7.1%对1.4%,p<0.0001)、30天平均医疗费用增加相关(16478美元对9306美元,p<0.0001),以及较低的5年生存中位数(3.28年对未达到)。在对年龄、收入五分位数、原发性癌症、分期、手术类型和新辅助化疗进行调整的多变量回归分析中,虚弱与30天并发症独立相关(OR 1.92,95%CI 1.63 - 2.27,p<0.0001),在对年龄、原发性癌症、分期、新辅助化疗和合并症进行调整时,与较低的5年生存率独立相关(HR 1.27,95%CI 1.16 - 1.38,p<0.0001)。使用ACG时这些结果相似。ROC分析显示两个指标的曲线下面积相似。
pFI和ACG测量的虚弱可预测包括术后发病率和死亡率增加以及5年生存率在内的预后。需要制定优化虚弱患者围手术期护理的策略。